Category: ACN Newswire

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

TOKYO and CAMBRIDGE, Mass., Sept. 3, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai

More

Yuzhou Group Holdings Company Limited (01628.HK) Announced the Official Effectiveness of Offshore Debt Restructuring, Marking a Key Step Toward Steady Development

HONG KONG, Sep 2, 2025 – (ACN Newswire via SeaPRwire.com) – On August 29, Yuzhou Group Holdings Company Limited (01628.HK) announced that its offshore debt management and restructuring efforts, which spanned over three years, have yielded decisive results. The offshore restructuring

More